Science1 distinct publisher2 min readPublished
The first update to recurrent pregnancy loss guidance since 2012 names sperm DNA fragmentation testing, then places it behind two other evaluations. The test itself is not new.
The Scientist · Science desk
Compiled by The ScientistSomething wrong?How this is made
Count and motility answer a logistics question: how many sperm there are and how well they move, which the Scientific American segment describes as a proxy for how likely one is to reach the egg [1]. Neither number describes the condition of the half-genome that arrives, and arrival is the first step of several before implantation and gestation [2].
Fragmentation is damage to that cargo, and it has been tied both to miscarriage and to lower IVF live birth rates [3][4]. The IVF end is where the reasoning is tightest. Assisted fertilisation solves delivery by construction; if half of the resulting embryo's DNA is broken, the segment argues, it is less likely to develop normally once implanted [5]. A clinic reading a clean semen analysis as clearance for the male partner has measured the one thing the procedure was already going to handle.
There is also a circularity in making the test a residual. Under the updated guidance it is reached only when miscarriage-tissue genetics and uterine structural testing have failed to explain the losses [6]. A test ordered exclusively at the end of a workup accumulates evidence only from patients who have already exhausted the other explanations, which is precisely the evidence base it would need to move forward in the sequence. Availability was never the obstacle: these assays have existed for decades [7].
The intervention side is thinner than the framing suggests. Richards told the podcast that in some cases the fix is as simple as cutting out alcohol, improving diet and exercise, and taking supplements [8]. "In some cases" is carrying the sentence. The transcript specifies no assay, no abnormal threshold, and no trial showing that a lower fragmentation score converts into a live birth [9]. That absence is the defensible reason a guideline committee would hold the test in reserve rather than hand it to every couple at intake, whatever the question Feltman put to her guest about teaching men this from the start [10].
The male-share numbers as relayed do not close either. Richards puts men's contribution at 50 percent of infertility problems, with about 20 percent of cases attributed to sperm alone and a further 30 to 40 percent to sperm in combination with the egg or other female factors [11][12][13]. Those components sum to 50 to 60 percent of cases involving sperm [14], so the 50 percent figure functions as a floor, not a partition. Meanwhile the cultural version arrived first, as the "sperm maxxing" trend of men eating better, drinking less and smoking less pot [15]. Diet advice reached the male half of the workup before the diagnostic did.
Ranked by verification strength, evidence, and original report placement.
Research has shown a connection between sperm DNA fragmentation, meaning breaks or other damage to the genetic information stored within sperm, and miscarriage.
Sperm DNA fragmentation has also been linked to lower IVF live birth rates.
Standard sperm tests measure count and motility, which ultimately shows how likely a sperm is to make it to the egg.
Conception is just the first of many steps to the implantation of a growing embryo, let alone the gestation of a healthy fetus.
In the updated ASRM recommendations, sperm DNA fragmentation testing is recommended not for all patients with repeated miscarriages, but only where genetic evaluations of miscarriage tissue and tests on the structure of the uterus have not revealed another cause.
Tests for DNA fragmentation in sperm exist and have been around for decades.
Follow any of these and your For You feed starts watching them — no settings page required.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Asserted linkages, no cited studies or assay specifics
One publisher, one podcast transcript. The miscarriage and IVF live-birth associations are asserted without study citations or effect sizes, the mechanistic rationale is offered as plausibility, and the transcript names no assay, no abnormal threshold, and no interventional evidence. The one hard, checkable element is the described content and sequencing of the ASRM update.
Guideline-listed, third-line only, uptake unmeasured
There is one concrete institutional adoption event - ASRM naming sperm DNA fragmentation testing in updated recurrent pregnancy loss guidance - and the tests themselves have existed for decades. But the recommendation is restricted to patients whose tissue genetics and uterine evaluation were unrevealing, and the source reports no test volumes, clinic uptake, vendors, or payer coverage.
Framing runs ahead of the cited evidence
The episode's 'good news / even better news' framing implies a straightforward path from testing to a healthy pregnancy via alcohol reduction, diet, exercise and supplements, while the same transcript supplies no assay, no threshold, and no outcome study for that path, and the guest disclaims expertise on the supplement literature. Prevalence figures are also relayed inconsistently. The overstatement is one of framing and certainty, not of fabricated facts: the guideline change itself is reported accurately and with its limiting condition intact.
Publisher promotes its own feature amid a subscription appeal
The interview is Scientific American discussing a recent Scientific American story with its author, and the transcript body carries an explicit subscription solicitation. That aligns editorial incentives with an upbeat, engagement-friendly framing of the guest's own reporting; no commercial sponsor, test vendor, or clinic financial interest is disclosed or evidenced in the source.
Single publisher, single transcript, unverified guideline text
Confidence is limited by a one-source, one-publisher cluster in which the key scientific claims are relayed second-hand by a journalist and the guideline wording is paraphrased rather than quoted. The guideline change and the sequencing detail are specific enough to be reasonably reliable; the causal and prevalence claims are not independently corroborated here.
science
Psilocybin Heads Into Anorexia Trials, Where the Bar for Progress Is a 5% Death Rate1 distinct publisher
science
Psilocybin's 'oneness' now has a brain-network correlate, and it was found by sorting people on self-report1 distinct publisher
science
Drone delivery stopped being a demo: thousands of tethered pod drops a day in Arkansas and Texas1 distinct publisher
science
One thorium site in four: the crystal detail that makes a solid-state nuclear clock buildable1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.
1 article · August 26, 2026